Clinical Trials

Are you an adult with heart failure and an implanted CardioMEMS pulmonary artery pressure (PAP) monitor? This study is investigating whether psychological stress can make the symptoms of heart failure worse. Participants of this study will have their blood pressure monitored and their blood drawn after undergoing mental stress in a controlled setting, within a laboratory. To participate in this study, you must be at least 18 years old. This study takes place in New Haven, Connecticut.

Do you have heart failure and need treatment with intravenous (IV) diuretics? This study is exploring the use of chloride supplementation in people with heart failure who require treatment with IV diuretics, which are used to help rid your body of excess water and salt. To participate in this study, you must have heart failure with signs of volume overload (rales, edema, elevated jugular venous pressure [JVP], or weight gain of at least 5 pounds) requiring treatment with IV diuretics. This study takes place in New Haven, Connecticut.

Do you or your child have severe asthma that is not easily controlled by inhaled corticosteroids? This study evaluates the use of five different asthma medicines to treat adults and adolescents with severe asthma. To participate in this study, you or your child must be 12 years old or older. This study takes place in multiple locations across the United States.

Have you been diagnosed with obstructive sleep apnea (OSA) and been referred to the Yale New Haven Hospital Sleep Center for continuous positive airway pressure (CPAP) treatment? This study is examining how the features that can raise or lower the risk of OSA can impact how well CPAP works in an individual. Researchers will use detailed sleep studies to determine which features contribute to OSA. Results from this study will help researchers develop treatment plans that can lead to personalized OSA treatments to improve patient lives. To participate in this study, you must be at least 19 years old. This study takes place in North Haven, Connecticut.

Are you an adult female with LAM? If so, you may be able to participate in this clinical study where researchers are observing patients who are taking or have taken a certain kind of medication, mammalian target of rapamycin (mTOR), to treat lymphangioleiomyomatosis, also known as LAM. You must be at least 18 years old to take part. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota, Missouri, New York, Ohio, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, and Washington.

The goal of this clinical trial is to compare different types of blood transfusions for critically injured patients who require large-volume blood transfusions. Participants must be at least 15 years old and need a massive blood transfusion. The study is taking place in locations in Alabama, California, Louisiana, Maryland, Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington, and Wisconsin.

Have you or your child been diagnosed with a blood disorder? If so, you (or they) may be able to participate in a clinical study where researchers are studying a type of infusion using cord blood. Participants can be of any age but must have a blood disorder diagnosed by their doctor. The study is taking place in locations in Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New York, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, Washington, Washington, D.C., West Virginia, and Wisconsin.

Are you 15 to 40 years old and have severe sickle cell disease? This study is comparing long-term outcomes for patients who receive blood and bone marrow transplants and those who receive standard treatment with medicines. Participants also have an option of contributing blood samples to be stored for future research. Participants must be 15 to 40 years old and have severe sickle cell disease. This study is located in Madison, Wisconsin.